These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 19096723)

  • 1. Causal Vaccine Effects on Binary Postinfection Outcomes.
    Hudgens MG; Halloran ME
    J Am Stat Assoc; 2006 Mar; 101(473):51-64. PubMed ID: 19096723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bayesian approach to estimating causal vaccine effects on binary post-infection outcomes.
    Zhou J; Chu H; Hudgens MG; Halloran ME
    Stat Med; 2016 Jan; 35(1):53-64. PubMed ID: 26194767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Causal inference for vaccine effects on infectiousness.
    Halloran ME; Hudgens MG
    Int J Biostat; 2012 Jan; 8(2):. PubMed ID: 22499732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity Analyses Comparing Time-to-Event Outcomes Existing Only in a Subset Selected Postrandomization.
    Shepherd BE; Gilbert PB; Lumley T
    J Am Stat Assoc; 2007 Jun; 102(478):573-82. PubMed ID: 19122791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials.
    Gilbert PB; Bosch RJ; Hudgens MG
    Biometrics; 2003 Sep; 59(3):531-41. PubMed ID: 14601754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bounding the infectiousness effect in vaccine trials.
    VanderWeele TJ; Tchetgen Tchetgen EJ
    Epidemiology; 2011 Sep; 22(5):686-93. PubMed ID: 21753730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity analyses comparing outcomes only existing in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trials.
    Shepherd BE; Gilbert PB; Jemiai Y; Rotnitzky A
    Biometrics; 2006 Jun; 62(2):332-42. PubMed ID: 16918897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applying the estimand and target trial frameworks to external control analyses using observational data: a case study in the solid tumor setting.
    Polito L; Liang Q; Pal N; Mpofu P; Sawas A; Humblet O; Rufibach K; Heinzmann D
    Front Pharmacol; 2024; 15():1223858. PubMed ID: 38344177
    [No Abstract]   [Full Text] [Related]  

  • 9. Assessing the ratio of means as a causal estimand in clinical endpoint bioequivalence studies in the presence of intercurrent events.
    Lou Y; Jones MP; Sun W
    Stat Med; 2019 Nov; 38(27):5214-5235. PubMed ID: 31621943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifiability of causal effects for binary variables with baseline data missing due to death.
    Yan W; Hu Y; Geng Z
    Biometrics; 2012 Mar; 68(1):121-8. PubMed ID: 21838813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knowledge, attitudes, and beliefs of school nurses and personnel and associations with nonmedical immunization exemptions.
    Salmon DA; Moulton LH; Omer SB; Chace LM; Klassen A; Talebian P; Halsey NA
    Pediatrics; 2004 Jun; 113(6):e552-9. PubMed ID: 15173536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian inference for a principal stratum estimand to assess the treatment effect in a subgroup characterized by postrandomization event occurrence.
    Magnusson BP; Schmidli H; Rouyrre N; Scharfstein DO
    Stat Med; 2019 Oct; 38(23):4761-4771. PubMed ID: 31386219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partially hidden Markov model for time-varying principal stratification in HIV prevention trials.
    Dai JY; Gilbert PB; Mâsse BR
    J Am Stat Assoc; 2012 Mar; 107(497):52-65. PubMed ID: 23667279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating causal effects of treatment in RCTs with provider and subject noncompliance.
    Sheng E; Li W; Zhou XH
    Stat Med; 2019 Feb; 38(5):738-750. PubMed ID: 30347462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Causal inference methods to assess safety upper bounds in randomized trials with noncompliance.
    Wang Y; Berlin JA; Pinheiro J; Wilcox MA
    Clin Trials; 2015 Jun; 12(3):265-75. PubMed ID: 25733675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of the average causal effect among subgroups defined by post-treatment variables.
    Matsuyama Y; Morita S
    Clin Trials; 2006; 3(1):1-9. PubMed ID: 16539085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the Operational Characteristics of the Individual Causal Association as a Metric of Surrogacy in the Binary Continuous Setting.
    Ong F; Molenberghs G; Callegaro A; Van der Elst W; Stijven F; Verbeke G; Van Keilegom I; Alonso A
    Pharm Stat; 2024 Sep; ():. PubMed ID: 39343430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Commentary on "Principal stratification - a goal or a tool?" by Judea Pearl.
    Gilbert PB; Hudgens MG; Wolfson J
    Int J Biostat; 2011; 7(1):Article 36. PubMed ID: 22049267
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.